Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Viral Hepatitis"
DOI: 10.1111/jvh.13738
Abstract: Chronic hepatitis C virus (HCV) infection has the greatest health impact in patients with advanced liver disease. The direct‐acting antiviral (DAA) regimen glecaprevir/pibrentasvir (G/P) is approved for treatment of HCV‐infected patients without cirrhosis and with… read more here.
Keywords: markers advanced; safety; advanced liver; liver disease ... See more keywords